GSK secures first lung cancer approval, validating $10.6bn Nuvalent bet
Just days after completing a $10.6bn takeover of lung cancer biotech Nuvalent, GSK is already reaping the rewards with Jideytro…
23 Jul 2026
Affinia Therapeutics receives FDA orphan drug designation for AFTX-201
Affinia Therapeutics has received the US Food and Drug Administration (FDA) orphan drug designation for AFTX-201, a treatment in development for BAG3-associated dilated cardiomyopathy (DCM). The gene therapy is under…
23 Jul 2026
Evogene and ELEO to develop new oral PCSK9 inhibitors
Evogene and ELEO have entered a scientific collaboration aimed at discovering and developing new oral small-molecule inhibitors targeting the Proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway for hyperlipidemia and cardiovascular…
23 Jul 2026
Crystalys banks $130m to progress gout drug, plan for commercial readiness
Crystalys Therapeutics has secured $130m in a Series B raise to push its gout therapy, dotinurad, further down the pipeline, while gearing the drug up for commercialisation – potentially poising…
22 Jul 2026
US generic tariff reprieve on the rocks as Trump proposes 100% rate in 2028
Following a period of immunity from US import tariffs, the global generics sector may now have to contend with similar taxes to the branded drug industry as President Donald Trump…
22 Jul 2026
Kyowa Kirin EMEA’s Crysvita approved by EC for infants with XLH
Kyowa Kirin subsidiary Kyowa Kirin EMEA has received approval from the European Commission (EC) to expand the use of Crysvita (burosumab) for treating X-linked hypophosphataemia (XLH) in infants aged one…
22 Jul 2026
Cellares and Papillon partner for PPL-001 manufacturing automation
Cellares and Papillon Therapeutics have entered a partnership to automate the manufacturing of PPL-001, an investigational therapy developed by the latter for Friedreich’s ataxia (FA), a rare inherited neurodegenerative disorder.…